BioWorld

Sep. 10, 2004

SGX, Roche Partner To Use FAST To Discover Antivirals

Entering the first major pharmaceutical deal for its Fragments of Active Structures drug discovery technology, Structural GenomiX formed an alliance with F. Hoffmann-La Roche Ltd. to discover new antiviral therapeutics. (BioWorld Today) Read More

InKine, FDA Agree On SPA For INKP-102 Phase III Trial

Transcytosis Research Lending Hope In Long Fight Against HIV

Push For Public Posting Of Clinical Trial Data Continues

Graffinity Closes Merger With MyoContract, Forms Santhera

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for April 27, 2026.

Detecting the invisible: minimal residual disease at AACR 2026

BioWorld Science

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...

Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

BioWorld Science

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...